日本感染症学雑誌第81巻第5号

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "日本感染症学雑誌第81巻第5号"

Transcription

1

2 Fig.1 Testprincipleof DUOI µ

3 Table1 HIV antigenantibodydetectionassay Assaykit DUO GenscreenPlus HIV AgAb Enzygnost HIV Integral Method ELFA ELFA ELISA ELISA Solidphase Antibody detection HIV1gp16(protein) HIV1groupO gp41 (synthetic) HIV2gp6(synthetic), biotinylated HIV1gp41, HIV1groupO gp41 HIV2gp6 (syntheticpeptide) HIV1gp16 (recombinant) HIV1groupO gp41 (synthetic) HIV2gp6(synthetic) HIV1gp41(recombinant andsynthetic) HIV1groupO gp41 (recombinant) HIV2gp6(recombinant) Antigen detection Antip24mouse monoclonal Antip24mouse monoclonal Antip24mouse monoclonal Antip24rabbit polyclonal Conjugate Antibody detection HIV1gp16(protein) HIV1groupO gp41 (synthetic) HIV2gp6(synthetic), biotinylated AntihumanIgGmouse monoclonallabeledwith ALP HIV1gp41, HIV1groupO gp41, HIV2gp6(synthetic) labeledwithpod HIV1gp41(recombinant andsynthetic) HIV1groupO gp41 (synthetic) HIV2gp6(synthetic), biotinylated Antigen detection Antip24rabbitpolyclonal (biotinylated) Antip24rabbitpolyclonal (biotinylated) Antip24sheeppolyclonal (biotinylated) Antip24mouse monoclonal(biotinylated) Samplevolume(μL) Time(min) Support VIDASautomated analyzer VIDASautomated analyzer Microplate Microplate µ µ µ

4 Table2 ResultsofHIVpositiveand negative specimensby 11HIVpositive plasmaspecimens 1,228HIVnegative plasmaspecimens Sensitivity 1% (11/11) Specificity 99.8% (1,225/1,228) Resultsof Positive 11 Negative 1,225 Table Resultsof falsepositivespecimensbyotherassays Antigenantibodydetectionassay Antibodyassay NAT sampleno. DUO Genscreen PlusHIV AgAb EnzygnostHIV Integral PA (GENEDIA HIV 1/2Mix) WB (LABBLOT 1,2) AMPLICOR HIV1Monitor Ver.1.5 TV a c copies/ml X <4 X <4 B <4 a TV:testvalue<.25:Negative,.25:Positive b TV:testvalue<.25:Negative,.25 TV<.5:Borderline,.5:Positive c.:cutofindex

5 Table4 Resultsof DUO falsepositivespecimensby NAT (AMPLICOR HIV1Monitor Ver.1.5) WB (LABBLOT 1,2) PA (GENEDIA HIV 1/2Mix) DUO Sample No. TV a.6 GM66 HIV1p GM6 6.1 GM GM1.45 GM15..4 GM69. GM GM82..9 GM GM GM15.2 GM11.6 GM1 a TV:testvalue<.25:Negative,.25 TV<.5:Borderline,.5:Positive b TV:testvalue<.25:Negative,.25:Positive Table5 ResultsofHIV antigenantibodydetectionassay,antibodyassay,antigenassay,andnucleic acidtest(nat)onworldwidehiv PerformancePanel(WWRB2) NAT Antibodyassay Antigenantibodydetectionassay WWRB2 RocheRNA RTPCR a EIA (AbbotHIV 1/2) a Enzygnost HIV Integral GenscreenPlus HIV AgAb c Genotype No. 1.2 O A 2.1 G G 4.9 A G HIV G 8.11 A 9. negative HIV C 12. A D 1.9 D D D C C C B 2.5 E E E HIV2 25. B B/D 2.22 F B 29.1 negative a Datafrom paneldatasheet b TV:testvalue<.25:Negative,.25:Positive c.:cutofindex

6 Table6 Comparison ofdetection limitsby antigenantibody detection assaysusing WorldwideHIV PerformancePanel (WWRB2) Genotype PanelNo. Antigenantibody detectionassay 1:1 1:1 2 1:1 1:1 4 1:1 5 1:1 6 A WWRB22 (TV a ) VIDUSHIV DUO ( ) Genscreen( c ) Enzygnost() (19.46) d (>1.86) (16.6) (1.51) (>1.86) (> 6.1) (1.41) (1.9) (>1.86) (> 6.1) (2.42) (.) (5.1) (.6) (.2) (.) (.) (.4) (.) B WWRB226 (TV) Genscreen() Enzygnost() (22.5) (>1.86) (2.8) (11.) (>1.86) (> 6.1) (15.1) (.12) (>1.86) (> 6.1) (.5) (.16) (>16.99) (.5) (.4) (.) (.16) () (.) (.61) C WWRB2 (TV) Genscreen() Enzygnost() (2.46) (>1.86) (.19) (1.91) (>1.86) (> 6.1) (16.8) (2.59) (>1.86) (> 6.1) (4.19) () (>16.56) (.15) (.55) (2.44) (.4) (.15) (.54) D WWRB2 (TV) Genscreen() Enzygnost() (12.4) (>1.86) (.64) (2.82) (>1.86) () (1.42) (.19) (2.) (1.5) (.2) () (.54) (.4) () (.2) (.) () E WWRB22 (TV) Genscreen() Enzygnost() (1.58) (>1.86) (11.4) (9.9) (>1.86) () (.4) (1.2) (>1.86) () (.9) () (6.) (.) (.1) (.81) (.4) () F WWRB228 (TV) Genscreen() Enzygnost() (22.8) (>1.86) (.2) (1.4) (>1.86) () (.) (2.1) (>1.86) () (2.6) (.) (1.) (.24) (.6) (1.4) () (.1) (.42) G WWRB24 (TV) Genscreen() Enzygnost() (2.44) (>1.86) (2.54) (1.98) (>1.86) (> 6.1) (18.85) (4.94) (>1.86) (> 6.1) (9.2) (.5) (>15.2) (1.2) (1.4) () (2.) (.) (.2) (.48) O WWRB (TV) Genscreen() Enzygnost() (2.1) (2.48) (>1.86) (> 6.1) (.8) (.2) (>1.86) (> 6.1) (.1) (1.4) (1.2) () (.4) (.) () (.2) (.4) () HIV2 WWRB1 (TV) Genscreen() Enzygnost() (24.92) (>1.86) (2.88) (9.49) (>1.86) (> 6.1) (1.4) (1.84) (11.9) () (.65) () (.45) (2.9) (.16) (.6) (.2) () a TV:testvalue<.25:Negative,.25:Positive b TV:testvalue<.25:Negative,.25 TV<.5:Borderline,.5:Positive c.:cutofindex d :nottested

7 Table ResultsofantigenantibodydetectionassaysandantibodyassayonHIV p24antigenmixedtiterperformancepanel(pra) PRA Antigenantibodydetectionassay Antigenassay Antibodyassay No. group VIDAS HIV DUO Genscreen PlusHIV AgAb Enzygnost HIV Integral EIA (AbbotHIV p24antigen) d PA (GENEDIA HIV 1/2Mix) a b negative c negative a Earlyseroconversionsample b Hightiterantibodysample c Negativecontrolsample d Datafrom paneldatasheet Table8 ComparisonofHIV p24antigendetectionlimitusingtwofolddilutedspecimensofculturedisolatehiv1ib Assay Twofolddilutedspecimen Antigen assay P24I p24ag pg/ml a Antigenantibody detection assay DUO GenscreenPlusHIV AgAb EnzygnostHIV Integral TV c d a p24agpg/ml:<.:negative,.and<5.:equivocal, 5.:Positive b TV:testvalue<.25:Negative,.25:Positive c TV:testvalue<.25:Negative,.25 TV<.5:Borderline,.5:Positive d.:cutofindex

8 Table9 Comparisonofantigendetectionlimitsbyantigenantibodydetectionassaysusingantigenpositivespecimensin thepanel PanelNo. Agvolume Antigenantibody detectionassay 1:1 1:2 1:4 1:8 1:16 1:2 1:64 1:128 p24antigen detectionlimits PRB964 (AK) 256.2pg/mL DUO TV a GenscreenPlus c HIV AgAb EnzygnostHIV Integral d. 4.pg/mL 2.pg/mL 2.pg/mL 128.1pg/mL PRA5 11.pg/mL DUO GenscreenHIV AgAb EnzygnostHIV Integral TV TV pg/mL 56.5pg/mL 56.5pg/mL 11.pg/mL PRA1 9.pg/mL DUO GenscreenHIV AgAb EnzygnostHIV Integral TV TV pg/mL 9.pg/mL 9.pg/mL 9.pg/mL a TV:testvalue<.25:Negative,.25:Positive b TV:testvalue<.25:Negative,.25 TV<.5:Borderline,.5:Positive c.:cutofindex d :nottested

9 Table1 ComparisonoftheperformanceofHIV antigenantibodydetectionassay,antigenassay,nucleicacidtest(nat)andantibodyassayon1hiv1seroconversionpanels Antibodyassay NAT Antigenassay Antigenantibodydetectionassay Days since 1st bleed PanelNo. EIA (Abbot HIV 1/2) a PA (GENEDIA HIV 1/2Mix) RocheRNA RTPCR a Abbot HIVAg a P24I Enzygnost HIV Integral Genscreen PlusHIVAgAb VIDAS HIV DUO VIDAS HIV pg/ml e d TV c.52 f PRB (AK) > >4 > >4 > PRB91.4 (AL) PRB (AM)2 >4. >6.5 > PRB99(E)4.6.1 (AN) >4. > >4. > >6.5 > PRB (AU) > > PRB (BA) >4. > >4. > PRB (BB) > > PRB (BC) > PRB (BD) >4..45 > PRB (BE) > adatafrom paneldatasheet btv:testvalue<.25:negative,.25:positive ctv:testvalue<.25:negative,.25 TV<.5:Borderline,.5:Positive d.:cutofindex ep24agpg/ml:<.:negative,.and<5.:equivocal, 5.:Positive f:nottested

10 et al. et al.

11 et al.

橡stat3.PDF

橡stat3.PDF 1 2 3 4 5 T + D T nod T + nod D T D T + nod T + D D + nod T + T + + T a a + c d b + d b b + d = 1 specificity c a + c = 1 sensitivity a a + b d c + d a + c a + b + c + d a + b a + b + c + d a + d a + b

More information

234 50cm

234 50cm 234 50cm () 1 10 2 3 4 1 5 6 2 2 1 7 ( ー ) っ ー っ 8 1 2 10 10 2m 4m 6m 15m 457-2472 585-1154 9 10 2 60 2 100 RC SRC 30 80 500 1 500 500 ) 10 B b A 2 A B 2m 457-2473 585-1154 11 20m a 2m 3 3 1m 75cm 120cm

More information

48 * *2

48 * *2 374-1- 17 2 1 1 B A C A C 48 *2 49-2- 2 176 176 *2 -3- B A A B B C A B A C 1 B C B C 2 B C 94 2 B C 3 1 6 2 8 1 177 C B C C C A D A A B A 7 B C C A 3 C A 187 187 C B 10 AC 187-4- 10 C C B B B B A B 2 BC

More information

PowerPoint プレゼンテーション

PowerPoint プレゼンテーション 0 1 2 3 4 5 6 1964 1978 7 0.0015+0.013 8 1 π 2 2 2 1 2 2 ( r 1 + r3 ) + π ( r2 + r3 ) 2 = +1,2100 9 10 11 1.9m 3 0.64m 3 12 13 14 15 16 17 () 0.095% 0.019% 1.29% (0.348%) 0.024% 0.0048% 0.32% (0.0864%)

More information

2 3

2 3 Sample 2 3 4 5 6 7 8 9 3 18 24 32 34 40 45 55 63 70 77 82 96 118 121 123 131 143 149 158 167 173 187 192 204 217 224 231 17 285 290 292 1 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38

More information

( ) ver.2015_01 2

( ) ver.2015_01 2 1 1.1 1.2 1.3 2 ( ) 2.1 2.2 2.3 2.4 3 4 4.1 4.2 4.3 4.4 4.5 4.6 4.7 4.8 4.9 5 5.1 5.2 5.3 5.4 6 6.1 6.2 6.3 7 7.1 7.2 7.3 8 ver.2015_01 2 1 1.1 1.2 1.3 ver.2015_01 3 2 2.1 2.2 2.3 ver.2015_01 4 2.4 ver.2015_01

More information

広報さっぽろ 2016年8月号 厚別区

広報さっぽろ 2016年8月号 厚別区 8/119/10 P 2016 8 11 12 P4 P6 P6 P7 13 P4 14 15 P8 16 P6 17 18 19 20 P4 21 P4 22 P7 23 P6 P7 24 25 26 P4 P4 P6 27 P4 P7 28 P6 29 30 P4 P5 31 P5 P6 2016 9 1 2 3 P4 4 P4 5 P5 6 7 8 P4 9 10 P4 1 b 2 b 3 b

More information

H27 28 4 1 11,353 45 14 10 120 27 90 26 78 323 401 27 11,120 D A BC 11,120 H27 33 H26 38 H27 35 40 126,154 129,125 130,000 150,000 5,961 11,996 6,000 15,000 688,684 708,924 700,000 750,000 1300 H28

More information

北アルプス_燕岳~穂高_-2.doc

北アルプス_燕岳~穂高_-2.doc 1 ( )22 2001 2226 30 1300m 27kg 2 JR 1000 22 10 3 500-400 au 300 N 2763m 4 N N 10 N 500m PM9:00 5 ( 2 ) 7 23 2001 2226 10 N N 40 10 30 6 5m N N N 12 3 49 30 20 2922m 7 K ( ) U S N ( ) 50 15 N 35 (2758m)

More information

21 1 1 1 2 2 5 7 9 11 13 13 14 18 18 20 28 28 29 31 31 34 35 35 36 37 37 38 39 40 56 66 74 89 99 - ------ ------ -------------- ---------------- 1 10 2-2 8 5 26 ( ) 15 3 4 19 62 2,000 26 26 5 3 30 1 13

More information

CHEMOTHERAPY JUNE 1986

CHEMOTHERAPY JUNE 1986 VOL. 34 S-3 CHEMOTHERAPY Fig. 1 Structural formula of L-105 CHEMOTHERAPY JUNE 1986 VOL. 34 S-3 CHEMOTHERAPY Table 1 Antibacterial spectra of L-105 against gram negative anaerobic rods Inoculum 106 cells/ml

More information

あさひ indd

あさひ indd 2006. 0. 2 2006. 0. 4 30 8 70 2 65 65 40 65 62 300 2006. 0. 3 7 702 22 7 62802 7 385 50 7 385 50 8 385 50 0 2 390 526 4 2006. 0. 0 0 0 62 55 57 68 0 80 5000 24600 37200 0 70 267000 500000 600 2 70 70 267000

More information

1

1 1 1 2 3 4 2 3 4 5 R 6 7 1 2 3 4 1 2 3 4 8 1 1 2 3 4 1 2 3 9 10 R A 85 U 11 8605 66 E 8 8 0 0 6 U W 6 B 38 U W6B28 U 12 W A 65 14 U W A 5B 12 U 6B 65 13 R A 85 F 14 15 16 17 18 19 20 21 22 23 24 25 26 27

More information

Fig. 1. Structures of NM394, NAD-358 and NAD-245 Fig. 2. Typical HPLC chromatograms of NM394 in human plasma by organic solvent extraction method (a): Blank plasma (b): Plasma spiked with NM394 and internal

More information

04年度LS民法Ⅰ教材改訂版.PDF

04年度LS民法Ⅰ教材改訂版.PDF ?? A AB A B C AB A B A B A B A A B A 98 A B A B A B A B B A A B AB AB A B A BB A B A B A B A B A B A AB A B B A B AB A A C AB A C A A B A B B A B A B B A B A B B A B A B A B A B A B A B A B

More information

2009 Aida et al. Caries Res 2006;40 2000 100 % 78.7 88.0 96.6 98.8 98.8 98.8 100.0 100.0 100 75 69.4 50 75.3 74.8 73.3 73.1 73.0 72.4 71.8 71.7 51.7 40.2 69.4 68.8 73.6 25 22.3 32.8 21.9 22.9 22.1

More information

表1.eps

表1.eps Vol.1 C ontents 1 2 cell-free EMBO J Proc. Natl. Acad. Sci. USA NatureEMBO J 3 RNA NatureEMBO J Nature EMBO J 4 5 HCV HCV HCV HCV RNA HCV in situ 6 7 8 Nat Struct Mol Biol J Biol Chem Nat Commun J Virol

More information

Section Section Section Table of Contents Section 6 Section 7 Section 8 Section 4 Section 0 Section 5 Section 9 Section Section Section Section 4 Section 5 Section 9 Section 0 Section Section 6 Section

More information

1 P2 P P3P4 P5P8 P9P10 P11 P12

1 P2 P P3P4 P5P8 P9P10 P11 P12 1 P2 P14 2 3 4 5 1 P3P4 P5P8 P9P10 P11 P12 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 & 11 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 2 1! 3 2 3! 4 4 3 5 6 I 7 8 P7 P7I P5 9 P5! 10 4!! 11 5 03-5220-8520

More information

WECPNL = LA +10log10 N 27 N = N 2 + 3N3 + 10( N1 + N 4) L A N N N N N 1 2 3 4 Lden Lden Lden Lden LAE L pa pa 2 a /10 LpA = 20 log 10 ( pa = p 10 ) n na p0 p na n an n p0 2 Lp p L p

More information

3.....ren

3.....ren 823 2011 329 20 11 20 48.3 90.5 20 40 21 12 16 22 3 23 50 50 50 1 54 2 55 3 56 57 49 330 823 2011 6 0.3 0.7 1.0 3 1 0.3 0.7 1.0 5 m 3 m 3 m 5 m 5 3 m 1 2 5001,000 3 50 52 mm 4 0.1 1 50 823 2011 331 5 10

More information

- 1 -

- 1 - - 1 - HIV cmc cmc - 2 - cmc() ( ) 5-3 - - 4 - (1) (2) (3) ( ) - 5 - 0537-73-2662 0537-35-2971 0548-63-1251 9 00 16 00-6 - - 7 - 2 3 4 5 6 1,328 1,848 2,368 2,888 3,408-8 - - 9 - - 10 - - 11 - 3-12 - (

More information

Ab-Match Assembly Human PAP1 (REG3a) Kit

Ab-Match Assembly Human PAP1 (REG3a) Kit CODE No. 323 For Research Use Only, Not for use in diagnostic procedures. Ab-Match Assembly Human PAP1 (REG3α) Kit For technical material or related information, please refer to http://ruo.mbl.co.jp/product/abmatch/abmatch.html.

More information

橡6 中表紙(教育施設).PDF

橡6 中表紙(教育施設).PDF 10 i ii 14 1 2 52 53 55 56 57 63 2 3 5 6 13 13 14 14 15 1 3 10 3 4 50 11 7 6 1 45,813.68 19,120.95 3 17,979.75 63,793.43 2,501.74 1,458.27 23 4,226.95 76 2,277.28 17 1,264.41 5 1,768.60 26 2,378.96 9 2,126.92

More information

PX-047A Series

PX-047A Series B K L & L & A B C D E F A B A B C A B C A B A B A B C D E F G P BB H I y y & & K L L & & K L L L L & & & & L d L & & & & L L & & & L & & & & L & & & & & & & & L L L L L L & & & A B C D E F G

More information

外国語教育センタージャーナル第9号

外国語教育センタージャーナル第9号 1. 1 35 45 2. 1 2 2 2013 5 1 31 2 40 3 37 4 40 2 17 2 5 165 148 9 4 4 4 3 1 Dörnyei(2001) 2 3 2 119 2 60 2 4 1 1 30 1 2 2 6 4 3 3.1 5 3 5 90 4 5 120 6 PPT K-POP 3.2 10 40 7 7 2005 10 8 5 9 6 7 3 5 8 9

More information

〈企業特集:検査機器・試薬・技術の新たな展開〉新規マイコプラズマ抗原検査キット—プロラスト®Myco

〈企業特集:検査機器・試薬・技術の新たな展開〉新規マイコプラズマ抗原検査キット—プロラスト®Myco New immunochromatographic assay kit for Mycoplasma pneumoniae infection 'PRORAST Myco' Shohei Ohshima, Yasushi Shimada, Atsuko Minagawa, Kazuyuki Sugiyama and Yumiko Hirayama Mycoplasma pneumoniae infection

More information

vol.31_H1-H4.ai

vol.31_H1-H4.ai http://www.jmdp.or.jp/ http://www.donorsnet.jp/ CONTENTS 29 8,715 Vol. 31 2 3 ac ad bc bd ab cd 4 Point! Point! Point! 5 Point! Point! 6 7 314 611 122 4 125 2 72 2 102 3 2 260 312 0 3 14 3 14 18 14 60

More information

2015taisetumatome.rtf

2015taisetumatome.rtf B B B( ) B3 - B3 1 3g 1/3 B 1. B1() B1() 2. B2() B2() 3. B5() B5() 4. B6() B6()( ) 5. B12() B12() 6. 1q60 160m 50m 50m 20m 8520 80 10 64 5075 30 80 B B 1 30 BB BC EPA . ?? 6 C E C 1 30 1 0.4mg4

More information

産衛誌57-4たより.indb

産衛誌57-4たより.indb A89 26 7 1 9 4 33 1 87 A90 24 A91 23 ACOH2014 A92 4 1 2 3 4 5 6 7 A93 A94 A95 A96 A97 A98 A99 A100 A101 27 8 1 9 A102 4 33 A103 A104 26 3 140 27 1 A105 27 A106 A107 A108 A109 A110 A111 A112 A113 et al

More information

-1 - -2 - -3 - -4 - -5 - -6 - -7 - -8 - -9- 44-10 - -11 - - 12 - - 13 - - 14 - - 15 - - 16 - - 17 - - 18 - - 19 - - 20 - - 21 - - 22 - - 23 - - 24 - - 25 - - 26 - - 27 - 372 304-28 - - 29 - - 30 - - 31

More information

10 : 3010 : 54 1F Annex 1! 1 15:3015 : 58 1F Annex 1

10 : 3010 : 54 1F Annex 1! 1 15:3015 : 58 1F Annex 1 4 16 1 10:0010 : 24 1F Annex 1! 2 15:0015 : 24 1F Annex 1!! 10 : 3010 : 54 1F Annex 1! 1 15:3015 : 58 1F Annex 1 ! 2 10:0010 : 28 1F Annex 1 3 15:0015 : 28 1F Annex 1 4 10:3010 : 58 1F Annex 1 1 15:3015

More information

140 120 100 80 60 40 20 0 115 107 102 99 95 97 95 97 98 100 64 72 37 60 50 53 50 36 32 18 H18 H19 H20 H21 H22 H23 H24 H25 H26 H27 1 100 () 80 60 40 20 0 1 19 16 10 11 6 8 9 5 10 35 76 83 73 68 46 44 H11

More information

A B 5 C 9 3.4 7 mm, 89 mm 7/89 = 3.4. π 3 6 π 6 6 = 6 π > 6, π > 3 : π > 3

A B 5 C 9 3.4 7 mm, 89 mm 7/89 = 3.4. π 3 6 π 6 6 = 6 π > 6, π > 3 : π > 3 π 9 3 7 4. π 3................................................. 3.3........................ 3.4 π.................... 4.5..................... 4 7...................... 7..................... 9 3 3. p

More information

Taro13-学習ノート表紙.PDF

Taro13-学習ノート表紙.PDF 10 11 12 13 13 14 15 18 22 27 30 32 A B C -1- -2- 1 2 A BC -3- -4- A B C -5- A B C -6- A B C -7- -8- 1-1 1-6 1-2 6-1 1-5 1-3 2-1 6-6 6-2 1-4 2-6 2-2 6-5 6-3 2-5 2-3 6-4 2-4 5-1 3-1 5-6 5-2 3-6 3-2 5-5

More information

東京で独立開業する。~独立開業マニュアル東弁版~

東京で独立開業する。~独立開業マニュアル東弁版~ 26 2010 2012 1 2013 2 2014 4 2006 2010 2015 2015 2013 2012 2012 2014 2012 2012 2014 2010 2015 / 2014 2013 2012 2014 2014 2014 2015 2015 2014 2014 2010 2009

More information

untitled

untitled ---------- - 1 - ----- 1 Q1 5 Q2 5 Q3 5 Q4 6 Q5 6 Q6 7 Q7 7 Q8 7 Q9 8 Q10 : 8 10 Q1 10 Q2 11 Q3 11 12 Q4 12 Q5 HBs HBc _12 Q6 HBe 12 Q7 13 Q8 NAT 15 Q9 15 Q10 15 Q11 HBs 16 Q12 HBV DNA 16 Q13 17-2 - Q14

More information

Table 1 Comparison with three HIV antigen and antibody screening tests Principle Detection of anti-hiv antibody gp41 HIV-1 Detection of HIV antigen Ti

Table 1 Comparison with three HIV antigen and antibody screening tests Principle Detection of anti-hiv antibody gp41 HIV-1 Detection of HIV antigen Ti 技術論文 ルミパルス f を用いた 同時検出試薬の 性能評価 石垣 卓也 1) 康 東天 2) 服部佳奈子 1) 山中 基子 1) 堀田多恵子 1) 1) 九州大学病院検査部 812-8582 福岡県福岡市東区馬出 3-1-1 2) 九州大学大学院医学研究院臨床検査医学分野 要 旨 今回 富士レビオ社が開発した第 4 世代検査試薬である ルミパルス 以下 本試薬 の性能評価を行っ た 同時再現性 日差再現性

More information

道路施設基本データ作成入力書式マニュアル(中国地方整備局版)平成20年10月

道路施設基本データ作成入力書式マニュアル(中国地方整備局版)平成20年10月 道 路 BOX 等 に 関 する 調 査 表 記 入 マニュアル D080 D080 道 路 B O X 基 本 この 調 査 表 は 道 路 BOX 等 に 関 する 基 本 的 データを 登 録 するためのものであ る なお ここで 取 扱 う 道 路 BOX 等 とは 管 理 する 道 路 に 対 し 平 行 ( 縦 断 方 向 ) しているアンダーパス 等 の 箇 所 などに 設 けられたボックスカルバート

More information

untitled

untitled COLAK Mehmed 11000 305 305 180 10000 9000 8000 160 140 120 7000 100 6000 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 80 GH IGF-1 GH GH 5 4 3 2 1 0 2 3 4 5

More information

14056095_06池澤.indd

14056095_06池澤.indd : 83 3 2014 12 1 2 1 : 1992 5 2 1 156 1992 2 1 2 : Joan Leigh Joan Green 117 83 3 1 2 3 1 2 1 8 3 : 1924 7 24 9 118 : 119 83 3 2 2, 3 10 1 2 1 120 : 3 1 121 83 3 2 2 1 1 2 3 122 : 2 2 2 123 83 3 10 6 10

More information

DiMAGE Scan Multi PRO

DiMAGE Scan Multi PRO J 9229-2887-26 P-A111 9229-2887-24 X-A110 9229-2887-24

More information

L1-a.dvi

L1-a.dvi 27 Q C [ ] cosθ sinθ. A θ < 2π sinθ cosθ A. A ϕ A, A cosϕ cosθ sinθ cosθ sinθ A sinθ cosθ sinθ +cosθ A, cosθ sinθ+sinθ+cosθ 2 + 2 cosθ A 2 A,A cosθ sinθ 2 +sinθ +cosθ 2 2 cos 2 θ+sin 2 θ+ 2 sin 2 θ +cos

More information

案内(最終2).indd

案内(最終2).indd 1 2 3 4 5 6 7 8 9 Y01a K01a Q01a T01a N01a S01a Y02b - Y04b K02a Q02a T02a N02a S02a Y05b - Y07b K03a Q03a T03a N03a S03a A01r Y10a Y11a K04a K05a Q04a Q05a T04b - T06b T08a N04a N05a S04a S05a Y12b -

More information

本文/本文

本文/本文 Ver.2 1アカウント 月 額 300 円 ( 税 抜 )の 利 用 料 追 加 になります 790-8509 愛 媛 県 松 山 市 大 手 町 1-11-4 受 付 時 間 / 平 日 AM8:00 PM22:00 土 日 祝 日 AM8:00 PM18:00 TEL 089(943)5001 FAX 089(921)0701

More information

12~

12~ R A C D B F E H I J K A A A A A A A A A A AD B C BD AD E A DB DB ADB D D DB BD A C D B F E AD B B B B BF AD B B DB B B B B DB B DB D D ADB D D D D D AB AD D DB AB B B B F D D B B D D BF DBF B B B FD

More information

76 3 B m n AB P m n AP : PB = m : n A P B P AB m : n m < n n AB Q Q m A B AQ : QB = m : n (m n) m > n m n Q AB m : n A B Q P AB Q AB 3. 3 A(1) B(3) C(

76 3 B m n AB P m n AP : PB = m : n A P B P AB m : n m < n n AB Q Q m A B AQ : QB = m : n (m n) m > n m n Q AB m : n A B Q P AB Q AB 3. 3 A(1) B(3) C( 3 3.1 3.1.1 1 1 A P a 1 a P a P P(a) a P(a) a P(a) a a 0 a = a a < 0 a = a a < b a > b A a b a B b B b a b A a 3.1 A() B(5) AB = 5 = 3 A(3) B(1) AB = 3 1 = A(a) B(b) AB AB = b a 3.1 (1) A(6) B(1) () A(

More information

補足情報

補足情報 1 危 険 警 告 注 意 2 3 4 5 6 7 8 1 2 3 4 5 9 6 7 8 9 10 10 1 2 11 1 12 1 2 13 3 4 14 1 2 15 3 4 5 16 1 2 3 17 1 2 3 4 18 19 20 21 22 23 1 2 3 4 5 24 6 7 8 9 10 25 26 27 28 6 1 2 7 8 9 3 4 5 29 1 2 警 告 3 4 5

More information

1 1 2 1 2.1.......................... 1 2.1.1........................... 2 2.1.2....................... 2 3 4 4 5 4.1.................................

1 1 2 1 2.1.......................... 1 2.1.1........................... 2 2.1.2....................... 2 3 4 4 5 4.1................................. CUI 13 2 14 1 1 2 1 2.1.......................... 1 2.1.1........................... 2 2.1.2....................... 2 3 4 4 5 4.1................................. 5 4.1.1...................... 5 4.1.2.......................

More information